Article
Cell Biology
Stephanie E. Reitsma, Jiaqing Pang, Vikram Raghunathan, Joseph J. Shatzel, Christina U. Lorentz, Erik Tucker, Andras Gruber, David Gailani, Owen J. T. McCarty, Cristina Puy
Summary: The interaction between FXIa and platelets may play a role in modulating thrombosis, with platelets found to enhance FXIa activity and promote coagulation while also inhibiting FXI activation.
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY
(2021)
Article
Hematology
Yuri Hayakawa, Shogo Tamura, Nobuaki Suzuki, Koya Odaira, Mahiru Tokoro, Fumika Kawashima, Fumihiko Hayakawa, Akira Takagi, Akira Katsumi, Atsuo Suzuki, Shuichi Okamoto, Takeshi Kanematsu, Tadashi Matsushita, Tetsuhito Kojima
Summary: A novel homozygous frameshift mutation in F11 was identified, resulting in a unique C-terminal structure in FXI and reduced extracellular secretion. Subsequent analysis revealed that a threonine at position 622 was essential for secretion, engaging in the formation of an alpha-helix motif. This study demonstrates the impact of the C-terminal structure, especially the alpha-helix motif, on FXI secretion.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS
(2021)
Article
Hematology
Amalie Carnbring Bonde, Jacob Lund, Jens Jacob Hansen, Jakob Rahr Winther, Per Franklin Nielsen, Stefan Zahn, Peter Tiainen, Ole Hvilsted Olsen, Helle Heibroch Petersen, Jais Rose Bjelke
Summary: The autolysis loop of factor X is shown to play a critical role in the regulation of its zymogen and active form. N-linked glycosylations introduced on the loop have position-specific effects on the interaction with inhibitors. In plasma-based assays, a modest decrease in FX activation rate can weaken the procoagulant response, even when down regulation of FXa activity by inhibitors is reduced.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS
(2022)
Review
Cardiac & Cardiovascular Systems
Raffaele De Caterina, Domenico Prisco, John W. Eikelboom
Summary: This paper reviews the potential of drugs targeting factor XI in anticoagulant therapy, along with ongoing clinical trials and future research directions.
EUROPEAN HEART JOURNAL
(2023)
Article
Cardiac & Cardiovascular Systems
Antonio Greco, Claudio Laudani, Marco Spagnolo, Federica Agnello, Denise Cristiana Faro, Simone Finocchiaro, Marco Legnazzi, Maria Sara Mauro, Placido Maria Mazzone, Giovanni Occhipinti, Carla Rochira, Lorenzo Scalia, Davide Capodanno
Summary: Therapeutic anticoagulation is used to prevent or treat blood clots, but it can increase the risk of bleeding. Inhibitors of Factor XI (FXI) show promise in reducing the adverse events of anticoagulation. Large-scale phase 3 clinical trials are needed to confirm the role of FXI inhibitors and determine their clinical indications.
Article
Nanoscience & Nanotechnology
E. Mohamed, A. Fitzgerald, T. Tsuzuki
Summary: Hemorrhage is a major cause of death in trauma, childbirth, and complex surgeries. Managing bleeding with topical hemostatic agents in the first hour after injury is crucial. Nanomaterials have enabled enhancements in current hemostatic materials and the development of new agents.
MATERIALS TODAY NANO
(2021)
Review
Cardiac & Cardiovascular Systems
Charles Hsu, Edward Hutt, Daniel M. Bloomfield, David Gailani, Jeffrey I. Weitz
Summary: Hemostasis and thrombosis are closely linked, with factor XI inhibitors potentially providing a safer alternative to current anticoagulants. Clinical studies are ongoing to determine the efficacy of factor XI inhibitors in attenuating thrombosis without disrupting hemostasis.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
(2021)
Article
Medical Laboratory Technology
Fiston Kasonga, Guillaume Feugray, Pierre Chamouni, Virginie Barbay, Marielle Fresel, Marie Helene Chretien, Sabine Brunel, Veronique Le Cam Duchez, Paul Billoir
Summary: This study aimed to assess whether thrombin generation assay (TGA) could be used to evaluate the hemorrhagic phenotype of patients with FXI deficiency. The results showed a slight decrease in thrombin generation in plasma samples of patients with FXI deficiency, while coagulation parameters increased during pregnancy in women with FXI deficiency.
CLINICA CHIMICA ACTA
(2021)
Article
Hematology
Kaushik Das, Shiva Keshava, Shabbir A. Ansari, Vijay Kondreddy, Charles T. Esmon, John H. Griffin, Usha R. Pendurthi, L. Vijaya Mohan Rao
Summary: Studies showed that FVIIa induces the release of EVs from endothelial cells through the EPCR-PAR1 signaling pathway, contributing to the hemostatic effect of FVIIa.
Review
Hematology
Sarah H. O'Brien, Ayesha Zia
Summary: This review highlights significant advances in pediatric hemostasis and thrombosis, including the development of bleeding assessment tools, laboratory evaluation of von Willebrand disease, and changes in clinical practice. It also discusses advancements in the management of hemostatic disorders and the prevention and treatment of pediatric venous thromboembolism. Despite these advancements, there are still unanswered questions and areas for further research.
Review
Hematology
James C. Fredenburgh, Jeffrey I. Weitz
Summary: Oral anticoagulants are widely used for preventing and treating thrombosis. Direct oral anticoagulants (DOACs) such as dabigatran and apixaban have replaced traditional anticoagulants. New DOACs like asundexian and milvexian, targeting FXIa, offer potential advantages over existing ones.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS
(2023)
Article
Hematology
Tanya T. Marar, Nicholas D. Martinez, Susan A. Maroney, Amy E. Siebert, Jie Wu, Timothy J. Stalker, Maurizio Tomaiuolo, Sinny Delacroix, Robert D. Simari, Alan E. Mast, Lawrence F. Brass
Summary: Loss of TFPI alpha expression does not lead to a global prothrombotic state in mice, indicating a local role in platelet release or display. TFPI alpha may accumulate at high concentrations in the narrow gaps between platelets at the site of injury, but this is not essential for a normal hemostatic response in mice.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS
(2021)
Article
Clinical Neurology
Yanjun Guo, Pamela M. Rist, Maria Sabater-Lleal, Paul de Vries, Nicholas Smith, Paul M. Ridker, Tobias Kurth, Daniel I. Chasman
Summary: The study found potential causality of increased FVIII, vWF, and phosphorylated fibrinopeptide A, as well as decreased fibrinogen in migraine susceptibility, especially for migraine with aura, revealing etiological relationships between hemostasis and migraine.
Review
Hematology
Noel C. Chan, Jeffrey I. Weitz
Summary: This review discusses the role of FXI and FXII in the pathogenesis of venous thromboembolism, explains why FXI is a better target, and describes the potential advantages of FXI inhibitors over currently available anticoagulants. It also provides an overview of the FXI inhibitors under development and their potential in addressing unmet needs in venous thromboembolism management.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
(2023)
Article
Hematology
Ophira Salomon, David Gailani
Summary: Therapeutic inhibitors targeting FXI(a) are being evaluated as potential treatments for preventing thrombosis, with the expectation of having a smaller impact on hemostasis than current anticoagulants targeting thrombin or factor Xa. However, some patients on these inhibitors may still experience abnormal bleeding or require emergent surgery, necessitating the development of strategies to address these situations. Treatment with antifibrinolytic agents and low doses of recombinant factor VIIa has been effective in preventing abnormal bleeding in FXI-deficient patients, suggesting a potential strategy for patients on therapeutic FXI(a) inhibitors experiencing bleeding or requiring invasive procedures.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS
(2022)
Article
Hematology
E. O. Artemenko, S. I. Obydennyi, K. S. Troyanova, G. A. Novichkova, D. Y. Nechipurenko, M. A. Panteleev
Summary: In this study, we investigated the adhesive properties of circulating plasma-derived and platelet-derived microvesicles (MVs) and their potential role in thrombus growth. The results showed that both types of MVs weakly bound fibrinogen but did not stably adhere to immobilized fibrinogen. Moreover, the presence of these MVs did not significantly affect thrombus formation. Therefore, MVs present in the plasma of healthy individuals are unlikely to directly contribute to thrombus formation under arterial flow conditions.
THROMBOSIS RESEARCH
(2024)
Letter
Hematology
Giuseppe Lippi, Camilla Mattiuzzi, Emmanuel J. Favaloro
THROMBOSIS RESEARCH
(2024)
Article
Hematology
Marium Malik, Maha Al-Ghafry, Abraham Haimed, Julia Su, Maribel Lema, Linda Shore-Lessersson, Suchitra S. Acharya
Summary: This study analyzed and evaluated leukemia-associated coagulopathy in newly diagnosed pediatric leukemia patients using CCTs and ROTEM. The results showed that fibrinogen and platelets played a significant role in causing coagulopathies in this population. This suggests the utility of using CCTs and ROTEM in the pediatric population to evaluate hemostatic function and guide blood product replacement.
THROMBOSIS RESEARCH
(2024)
Review
Hematology
Mohammad M. Elahi, Alexandra N. Witt, Edward L. G. Pryzdial, Paul B. McBeth
Summary: Thrombotic disease may be underdiagnosed in microgravity conditions, and the underlying factors are still poorly understood. A case of internal jugular vein thrombosis was recently diagnosed in a low-risk female astronaut, and six out of ten additional crew members showed risk factors for jugular venous flow. Observations in space and studies on Earth suggest that microgravity affects blood flow, coagulation, and vascular function.
THROMBOSIS RESEARCH
(2024)
Review
Hematology
Stian Ingemann-Molden, Christina Krogner Caspersen, Nanna Rolving, Anette Arbjerg Hojen, Frederikus A. Klok, Erik L. Grove, Barbara Cristina Brocki, Jane Andreasen
Summary: This study found that no single PROM covered all aspects considered important by PE patients. PROMs recommended in the ICHOM core set covered most aspects, but worrisome thoughts, hypervigilance around symptoms, and uncertainty of illness were not covered.
THROMBOSIS RESEARCH
(2024)
Article
Hematology
Haomin Yan, Tsutomu Sasaki, Yasufumi Gon, Kumiko Nishiyama, Hideaki Kanki, Hideki Mochizuki
Summary: The incidence of cancer-associated stroke has increased with the prolonged survival times of cancer patients. In this study, the researchers focused on the driver gene KRAS and found that KRAS mutations exacerbated neurological deficits after stroke and promoted tumor growth. They also identified the upregulation of pro-inflammatory responses and the promotion of STAT3 phosphorylation in mice with KRAS mutations. Additionally, the researchers found that colorectal cancer patients with stroke onset within 3 months after cancer diagnosis had a worse prognosis.
THROMBOSIS RESEARCH
(2024)
Letter
Hematology
Tomoki Togashi, Satomi Nagaya, Makiko Meguro-Horike, Haruto Matsumoto, Yuta Imai, Koichi Yamaguchi, Yoshinari Fujii, Haruka Moriya, Yuika Kikuchi, Ibuki Yasuda, Shin-ichi Horike, Eriko Morishita
THROMBOSIS RESEARCH
(2024)
Article
Hematology
Marta Najarro, Winnifer Briceno, Carmen Rodriguez, Alfonso Muriel, Sara Gonzalez, Ana Castillo, Ignacio Jara, Parth Rali, Catalin Toma, Behnood Bikdeli, David Jimenez
Summary: The CPES score is a useful tool in identifying the risk of hemodynamic deterioration in normotensive patients with acute PE, with acceptable C-statistic, excellent specificity, and low positive predictive value.
THROMBOSIS RESEARCH
(2024)
Article
Hematology
Lei Liu, Huifang Xu, Jian Wang, Haiyan Wang, Saisai Ren, Qian Huang, Mingyan Zhang, Hui Zhou, Chunyan Yang, Lu Jia, Yu Huang, Hao Zhang, Yanling Tao, Ying Li, Yanan Min
Summary: This study investigated the gut microbiota metabolites and cytokines, chemokines, and growth factors in patients with ITP and found their association with treatment responsiveness. The findings suggest that imbalanced secretion of cyto(chemo)kins/growth factors and inadequate levels of TMAO are characteristic of patients with ITP.
THROMBOSIS RESEARCH
(2024)
Article
Hematology
Roxanne Mcknight, Mohammad Salameh, Lee Ann Jones, Greta Anton, Lindsay Carter
Summary: This study evaluated the safety of fixed-dose heparin titration boluses in underweight patients with VTE. The results showed that although underweight patients required more frequent holding of heparin, there was no significant increase in bleeding risk.
THROMBOSIS RESEARCH
(2024)
